- $3.25bn
- $2.94bn
- $460.16m
U.S. RESEARCH ROUNDUP-Biontech, Honeywell International, Klaviyo
Brief: JPMorgan's Long Position In Zai Lab Decreases To 12.76% On June 4 - HKEX
Brief: Zai Lab Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis
Shares of Chinese brokerage Guolian Securities jump on acquisition plan
Brief: Zai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China
China's Zai Lab hits 3-month peak as NMPA approves lung cancer drug
Brief: Zai Lab Says China's NMPA Approved AUGTYROTM (REPOTRECTINIB)
China's Zai Lab Hong Kong stock jumps most in 16 months on revenue jump
Brief: JPMorgan Chase & Co's Long Position In Zai Lab Increases To 13.64% On April 23 - HKEX
Brief: JPMorgan Chase & Co's Long Position In Zai Lab Increases To 13.17% On April 16 - HKEX
Zai Lab up after lung cancer drug meets main goal in late-stage trial
Brief: Zai Lab Partner Bristol Myers Squibb Announces Confirmatory Trial For KRAZATI Meets Primary Endpoint
Brief: Zai Lab Says FY Net Loss $334.6 Million
Zai Lab Ltd expected to post a loss of 9 cents a share - Earnings Preview
Brief: Zai Lab Entered Into Uncommitted Facility Letter With The Bank Of China (Hong Kong) Limited
Brief: UBS Group AG's Long Position In Zai Lab Ltd Reduced To 4.95% On Feb 2 - HKEX
Brief: UBS Group AG's Short Position In Zai Lab Reduced To 1.95% On Jan 26 - HKEX
Brief: JPMorgan Chase & Co's Long Position In Zai Lab Increases To 11.50% On Jan 17 - HKEX
Brief: JPMorgan Chase & Co's Long Position In Ordinary Shares Of Zai Lab Reduced To 10.28% On Jan 12 - HKEX